Literature DB >> 18365166

[Retroperitoneal fibrosis].

S Burkhardt Soares1, S Kukuk, A S Brandt, A Fehr, S Roth.   

Abstract

Retroperitoneal Fibrosis (RPF) is a rare disease with peak incidence in the fifth to seventh decades of life. Its etiology remains to a great extent unclear; however, many characteristics of the disease suggest an autoimmune origin. Distinction is made between primary/idiopathic and secondary RPF. Symptoms may be general/nonspecific or localized (due to replacement or compression of organs). In addition to patient history, laboratory analysis and radiologic examinations, diagnosis often requires biopsy taken from the area affected. After restoring the function of involved (hollow) organs, medical therapy with prednisone, immunosuppressive drugs or tamoxifen is aimed at converting active disease to stable disease. However, some patients require ureteral surgery due to unsuccessful treatment. Life-long follow-up of patients is necessary since RPF can show a chronically relapsing course.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18365166     DOI: 10.1007/s00120-008-1705-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  58 in total

Review 1.  Ileal ureteral substitution in reconstructive urological surgery: is an antireflux procedure necessary?

Authors:  M Waldner; L Hertle; S Roth
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

2.  Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases.

Authors:  Renzo Marcolongo; Ivan Matteo Tavolini; Francesco Laveder; Moira Busa; Franco Noventa; Pierfrancesco Bassi; Gianpietro Semenzato
Journal:  Am J Med       Date:  2004-02-01       Impact factor: 4.965

3.  Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids.

Authors:  W Grotz; I von Zedtwitz; M Andre; P Schollmeyer
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

4.  Retroperitoneal fibrosis and ankylosing spondylitis: which links?

Authors:  Antonella Afeltra; Umberto Vespasiani Gentilucci; Carla Rabitti; Antonio Amoroso; Marco Caricato; Marta Vadacca; Sergio Valeri; Enrico M Zardi; Roberto Coppola; Antonio Picardi
Journal:  Semin Arthritis Rheum       Date:  2005-08       Impact factor: 5.532

5.  Omental sleeve to prevent recurrent retroperitoneal fibrosis under the ureter.

Authors:  G C Tresidder; J P Blandy; M Singh
Journal:  Urol Int       Date:  1972       Impact factor: 2.089

6.  Percutaneous implantation of subcutaneous prosthetic ureters: long-term outcome.

Authors:  M E Jabbour; F Desgrandchamps; E Angelescu; P Teillac; A Le Duc
Journal:  J Endourol       Date:  2001-08       Impact factor: 2.942

Review 7.  Chronic periaortitis: a spectrum of diseases.

Authors:  Augusto Vaglio; Carlo Buzio
Journal:  Curr Opin Rheumatol       Date:  2005-01       Impact factor: 5.006

8.  Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie's disease.

Authors:  Ekkehard W Hauck; Arne Hauptmann; Wolfgang Weidner; Gregor Bein; Holger Hackstein
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

9.  Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin.

Authors:  Davide Martorana; Augusto Vaglio; Paolo Greco; Adele Zanetti; Gabriella Moroni; Carlo Salvarani; Mario Savi; Carlo Buzio; Tauro M Neri
Journal:  Arthritis Rheum       Date:  2006-02-15

10.  The clinical significance of retroperitoneal fibrosis.

Authors:  L Koep; G D Zuidema
Journal:  Surgery       Date:  1977-03       Impact factor: 3.982

View more
  3 in total

1.  [Subacute lower back pain and acute kidney failure in a 47-year old man].

Authors:  T Tritschler; J Bleisch; A Al Rifai; E Marques Maggio; S Müller; R Schorn
Journal:  Internist (Berl)       Date:  2014-09       Impact factor: 0.743

2.  [Therapy of retroperitoneal fibrosis: functional therapeutic outcome].

Authors:  A S Brandt; S Kukuk; N M Dreger; E Müller; S Roth
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

3.  [Retroperitoneal fibrosis: development of a biomarker profile for diagnosis and therapy monitoring].

Authors:  S Kukuk; A Kretschmer; H Bruck; S Roth; A S Brandt
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.